MaxCyte Regulatory News (MXCT)

MaxCyte, Inc.

("MaxCyte" or the "Company")

Total Voting Rights

Maryland, USA - 30 November 2017: MaxCyte (LSE: MXCT, MXCR) announces that, following an exercise of options, 41,121 new shares of common stock of $0.01 each in the Company (the "Common Stock") were issued from the blocklisting facility granted 5 May 2017.

The total issued stock capital of the Company has consequently increased to 50,878,083 shares of Common Stock. There is no Common Stock held in treasury. Therefore, the total number of voting rights in the Company is 50,878,083. Stockholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the capital of the Company.

The Company also announces that, in accordance with the Company's intention disclosed in its circular dated 31 March 2017, the Company has effected the transfer of Common Stock held by an affiliate to its restricted line of Common Stock, with such stock to continue to be held by such affiliate in certificated form.

Following the issue of Common Stock from the blocklisting facility and following the effected transfer of the certain affiliate's stock to the restricted line, the number of unrestricted shares of Common Stock trading under the symbol 'MXCT' is 35,364,975 and the number of restricted shares of Common Stock trading under the symbol 'MXCR' is 15,513,108. The number of Common Stock capable of being issued under the blocklisting facility is 936,444 shares of Common Stock.

- ENDS -

For further information please contact:

About MaxCyte

MaxCyte (LSE: MXCT, MXCR) is a US-based global company driving the acceleration of the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines. The Company provides its patented, high-performance cell engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing, and cell therapy, including gene editing and immuno-oncology. With its robust delivery platform, MaxCyte's team of scientific experts helps its partners to unlock their product potential and solve problems. This platform allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large-scale, clinical and commercial grade cell engineering in a non-viral system and with low-toxicity concerns. The Company's cell-engineering platform is FDA-accredited, providing MaxCyte's customers and partners with an established regulatory path to commercialize cell-based medicines. MaxCyte is also developing CARMA, its proprietary, breakthrough platform in immuno-oncology, to rapidly manufacture CAR therapies for a broad range of cancer indications, including solid tumours where existing CAR-T approaches face significant challenges.

For more information, visit http://www.maxcyte.com/